drugset / Trial / NCT00622232
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine the long term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells with a focus on evaluating additional therapeutic benefits with respect to viral load and CD4 counts.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-01
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRX496-transduced autologous CD4 T cells | Cell therapy | 1e+10 cells | — |